Note on drug treatment of complete heart block

H. A. Fleming and Sheila M. Bailey
From The Regional Cardiac Unit, Papworth Hospital, Cambridge

Eight years of personal experience of long-acting isoprenaline in the treatment of chronic complete heart block is described. In selected patients the long-term results can be very satisfactory and examples are given. The isoprenaline infusion test is invaluable in selecting most patients who will not do well on long-acting isoprenaline. Of those who begin on treatment about half have done well. This form of treatment has proved useful before the setting up of a regional pacemaker service and it continues to be suitable in selected cases. It will continue to have an application in areas of the world where efficient pacemaker services cannot be provided.

In 1963 this Unit reported the use of long-acting isoprenaline (Saventrinone) in the treatment of complete heart block in 8 patients (Fleming and Mirams, 1963). Two of these had died before the report was published; 4 of the remaining 6 survive and are in good health at the time of writing 8 years later. This is a better result than might have been anticipated with the pacemakers available in 1962–63 in this region. Since then pacemakers and their problems have vastly improved and there is now a tendency to pace most patients with bradycardia. However, our own experience with long-acting isoprenaline has continued to be satisfactory in selected patients, and similar findings have been reported by Bluestone and Harris (1965), El-Nahas and Johnson (1966), and Redwood (1969).

We felt that the time had now come to review briefly our own experience with Saventrinone to date.

Subjects
We first present the 8 cases – the subject of the original report (Table).

Comment
In the individual patient the dose has varied from time to time and patients have needed a good deal of attention to detail to establish precisely the regimen which suited them best. This is not only essential to establish an adequate therapeutic effect but often to avoid important side effects.

Case 1 who has been on treatment for nearly 8 years can easily show that his wellbeing is dependent on his present dose. A small reduction will reduce his ventricular rate conspicuously and he will feel less well. He adjusts his own dose to fit in with seasonal variations in his activity.

Of the 4 patients who died, 2 did so in the early stages and one after 2 years of treatment. There were no necropesies in 2 of these cases but it is reasonable to assume that death was due to the heart condition and, in the third, necropsy revealed recent thrombotic occlusion of the right main coronary artery. One patient died from bronchial carcinoma after 3 years of uneventful Saventrinone treatment.

There were no important side effects in this group apart from slight diarrhoea at the beginning of treatment in 2 cases. Case 7 was recently found to have a tremor and palpitations in the morning but these were abolished without loss of rate by adjusting the regimen.

A further 12 patients presenting with symptomatic complete heart block remain on treatment with isoprenaline; 3 are men and 9 women. Their ages range from 46 to 82 years, with a mean of 68 years. The dosage ranges from 30–600 mg, with a mean of 230 mg daily. All patients have remained free from Adams-Stokes attacks and heart failure; they feel much better and have a new sense of wellbeing. The average duration of treatment is 2 years 1 month.

Examples
An 82-year-old active alderman was seen in March 1968 with a three-month story of ankle oedema and three weeks of frequent Adams-Stokes attacks. He was found to be in complete heart block with a ventricular rate of 25 a minute. The intravenous test with isoprenaline increased the ventricular rate to 70 a
minute without either side effects or extrasystoles. He has since been treated with isoprenaline 90 mg five times daily and has remained well and fully active without symptoms. The ventricular rate has never been noted to be below 55 a minute. He recently presented with anaemia (haemoglobin 6.8 g/100 ml) due to a gastrointestinal bleed. In spite of this his cardiac condition remained excellent. A temporary pacing catheter was inserted by the subclavian route to tide him over a gastrectomy for carcinoma of the stomach. Widespread metastases were found. He went back on his usual dose of isoprenaline by mouth and made an uneventful recovery until he died from carcinomatosis and pulmonary emboli some months later.

A 55-year-old woman was seen in March 1963 with a six-week story of frequent Adams-Stokes attacks and dyspnoea. She was in 2:1 block with a ventricular rate of 44 a minute and from her story it was likely that she had spells of asystole. She was treated with isoprenaline 210 mg a day and went into sinus rhythm with a rate of 100 a minute with occasional dropped beats. When the isoprenaline dose was reduced she reverted to 2:1 block. In 1965 the drug was temporarily stopped because of tremor and there was a recurrence of her symptoms. She was restarted on 80 mg three times a day. This cycle of events recurred in 1966 with severe Adams-Stokes attacks occurring when the drug was stopped and she was restarted on isoprenaline in six carefully graded doses totalling 450 mg a day. She remained symptom free until 1969 when she again temporarily complained of feeling jumpy and tremulous. In September 1970 these symptoms were very troublesome. Her treatment was adjusted by slight reduction in dose and on this she felt well. She remains on 450 mg a day taken in six doses. Her ventricular rate is 52 a minute and she is now aged 59 years.

**Saventrine failures**

Thirty-one other patients have been treated for a period with isoprenaline but 11 of these died: 1 from carcinoma of the rectum and the others from cardiac causes. The average age of death was 70 years and the average duration of treatment 1.3 years.

Thirteen have since been paced for the following reasons: continued Adams-Stokes attacks (5), ventricular ectopics (3), side effects of isoprenaline (3), continued heart failure (1), and failure to increase rate (1).

Two of these paced patients have since died. The remaining 11 are well. The remaining 7 patients form a mixed group: 2 became well without further treatment, 2 left the area and have been lost to follow-up, 1 reverted to sinus rhythm, 1 went into atrial fibrillation and felt well, and 1 had diarrhoea but refused pacing and continues on ephedrine.

**Intravenous isoprenaline test**

The test described by Redwood (1968) has proved invaluable in predicting those patients who may not do well on isoprenaline. This test was carried out in 13 of the 31 isoprenaline failure patients. The results indicated that 12 of these would not do well, showing either an increase in ventricular ectopic beats, lack of response to high dosage, extreme sensitivity or unpleasant side effects, particularly feelings of tension. Patients who have subsequently done well on isoprenaline all had good results with this test. One patient who increased her

### Table

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Dosage (mg)</th>
<th>Rate Before</th>
<th>Rate After</th>
<th>Duration of treatment (yr)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32</td>
<td>M</td>
<td>420</td>
<td>28-36</td>
<td>56</td>
<td>7 10/12</td>
<td>Well throughout</td>
</tr>
<tr>
<td>2</td>
<td>59</td>
<td>F</td>
<td>720-900</td>
<td>32</td>
<td>45</td>
<td>3 8/12</td>
<td>Well until 1966 when died from bronchial carcinoma</td>
</tr>
<tr>
<td>3</td>
<td>67</td>
<td>M</td>
<td>480</td>
<td>30</td>
<td>34-48</td>
<td>1/12</td>
<td>Died 9 days after discharge from hospital</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>M</td>
<td>150</td>
<td>33</td>
<td>90</td>
<td>4 12</td>
<td>Died from coronary – 1963</td>
</tr>
<tr>
<td>5</td>
<td>59</td>
<td>M</td>
<td>480</td>
<td>36</td>
<td>45</td>
<td>7 9/12</td>
<td>Continues very well despite small rate increase</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>F</td>
<td>180</td>
<td>40</td>
<td>60-80</td>
<td>7 7/12</td>
<td>Now aged 79, recurrent diverticulitis but otherwise well</td>
</tr>
<tr>
<td>7</td>
<td>52</td>
<td>F</td>
<td>390</td>
<td>40</td>
<td>65</td>
<td>5 6/12</td>
<td>Well; recent readjustment of treatment</td>
</tr>
<tr>
<td>8</td>
<td>55</td>
<td>F</td>
<td>720-900</td>
<td>15-54</td>
<td>38</td>
<td>2</td>
<td>Died 1965</td>
</tr>
</tbody>
</table>

---

**TABLE**

310 Fleming and Bailey
ventricular ectopics in the test was considered psychologically unsuitable for pacing and yet has done very well on isoprenaline.

A total of 51 patients have been treated with isoprenaline for a period of 91 patient years. Of these patients, 22 have continued satisfactorily for a period totalling 61 patient years; 23 patients have not done well.

These results show that approximately half the patients who have been treated with isoprenaline have done well. This proportion has been greatly increased since the intravenous isoprenaline infusion test was introduced. The introduction of simpler pacing systems in this region (Clarke, Evans, and Milstein, 1971) has extended the scope of long-term pacing but the authors feel that medical treatment still has a small but definite place. The economics of pacing (Whitaker, 1970) make it unlikely that with present methods (Sowton, 1968) all patients who might benefit can be fitted into a reliable service and, in some areas at least, drug treatment will continue to have a place in the management of the problem. Our feelings on the selection of cases are in agreement with those stated by Redwood (1969). Attention to the detail of the regimen and the timing, as well as the amount of the dose, is most important in the individual patient.

References

Requests for reprints to Dr. H. A. Fleming, Papworth Hospital, Papworth Everard, Cambridgeshire.
Note on drug treatment of complete heart block.

H A Fleming and S M Bailey

Br Heart J 1972 34: 309-311
doi: 10.1136/hrt.34.3.309

Updated information and services can be found at: http://heart.bmj.com/content/34/3/309.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/